A preliminary analysis showed that an immuno-oncology regimen in patients with intermediate hepatocellular carcinoma produced a significantly greater treatment benefit compared with transarterial chemoembolization (TACE). Immuno-oncology outperformed TACE in terms of efficacy in this group of patients. The study focused on patients with intermediate-stage hepatocellular carcinoma. The results are marked as preliminary, meaning this is an ongoing analysis. TACE is currently the standard local treatment method for intermediate HCC, but in this analysis it performed worse than the immuno-oncology regimen. The article reports that the difference in treatment benefit between the two approaches was statistically significant.